Peregrine Gold poised for follow-up drilling at exciting Tin Can gold discovery
Peregrine Gold to start follow-up drilling at the Tin Can gold discovery Initial drilling will extend mineralisation down plunge before testing along strike across the [more…]
Top 10 at 10: Sluggish nickel stocks stir, lithium junior inks ‘transformational’ development JV
Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. [more…]
Market Highlights: Fed spooks market, Reddit signs data deal with OpenAI, and 5 ASX small caps to watch
ASX to open lower after a fall on Wall Street Comments from three Fed officials spooked markets Reddit signed data deal with OpenAI Aussie [more…]
Long Shortz with Victory Metals: Unveiling a rare earth gem as North Stanmore shines bright
Stockhead’s Sarah Hughan sits down with Victory Metals (ASX:VTM) CEO and executive director Brendan Clark to get the short end of the long story on [more…]
Long Shortz with OD6 Metals: Hey hey hey, good old Splinter Rock’s here to stay
Stockhead’s Sarah Hughan sits down with OD6 Metals (ASX:OD6) managing director and CEO Brett Hazelden to get the short end of the long story on the [more…]
Chateau Tanunda: Here’s cheers to a grand resurgence
They are the father-and-daughter team restoring glory to an icon of the wine world. Wine entrepreneurs John and Michelle Gerber deserve their own chapter in [more…]
ASX funds and companies opening new doors for investors in private credit – Part 2
Private credit is a rapidly expanding asset class, projected to grow at a CAGR of 11% from 2022 to 2028 Finexia Financial Group aim to [more…]
Warren Buffett reveals secret stock sauce: Chubb
The palace intrigue around Warren Buffett’s multi-billion dollar secret Berkshire Hathaway investment has finally been put to the sword, with the swish of a 13F [more…]
Is this copper run overcooked?
Commbank mining analyst Vivek Dhar says base metal prices could have overdone themselves as copper and its cousins rise against traditional indicators MineLife’s Gavin Wendt [more…]
Immutep’s clinical trials are advancing rapidly; here are the next catalysts for investors
Immutep has a number ongoing clinical trials focusing on immuno-oncology The trials focus on the company’s lead drug, Efti, which is a soluble LAG-3 protein [more…]
